SCHEMBL4302000

SCHEMBL4302000

NNC(=O)COc1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OGG1 O15527 1/20 1.00
KDM4E B2RXH2 5/20 0.66
ALDH1A1 P00352 4/20 0.66
HPGD P15428 2/20 0.66
TDP1 Q9NUW8 2/20 0.66
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
MAPT P10636 6/20 0.62
LMNA P02545 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
GAA P10253 1/20 0.59
DAPK1 P53355 1/20 0.58
PIM3 Q86V86 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C19 P33261 1/20 0.58
MAPK1 P28482 1/20 0.56
TSHR P16473 1/20 0.56
TRPM4 Q8TD43 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28325522 0.94 OGG1 (0.89) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL10727418 0.85 OGG1 (0.74) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL15426831 0.84 OGG1 (0.73) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL6846901 0.84 OGG1 (0.72) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL3729668 0.82 OGG1 (0.69) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL15426820 0.81 OGG1 (0.69) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL1614613 0.81 KDM4E (0.72) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL12003962 0.81 MEN1 (0.80) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL27211583 0.81 KDM4E (0.77) OGG1KDM4EALDH1A1HPGDTDP1
SCHEMBL14638181 0.80 ALDH1A1 (0.74) OGG1KDM4EALDH1A1HPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104276974-B 1 urea phosphate glycosides acyltransferase inhibitor of N acetylglucosamines and its preparation method and application 华中农业大学 2017-04-05 CN claimed
US-12528819-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2026-01-20 US disclosed
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2025-05-06 US disclosed
US-12024525-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment AGENEBIO, INC. (US) 2024-07-02 US disclosed
CN-112601749-B Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉因生物股份有限公司 2024-03-26 CN disclosed
CN-112409363-B Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment 艾吉因生物股份有限公司 2023-11-14 CN disclosed
CN-116640143-A Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉因生物股份有限公司 2023-08-25 CN disclosed
EP-3555100-B1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO INC (US) 2023-05-10 EP disclosed
US-20230134844-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO, INC. 2023-05-04 US disclosed
US-20230107032-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-04-06 US disclosed
US-7638565-B2 Polyacetal resin composition POLYPLASTICS CO., LTD. (JP) 2009-12-29 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed
WO-2009131958-A2 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING TRIAZINE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2009-10-29 WO disclosed
WO-2009131958-A2 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING TRIAZINE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2009-10-29 WO disclosed
US-20090264433-A1 Compounds, Compositions and Methods Comprising Triazine Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-10-22 US disclosed
US-20090264433-A1 Compounds, Compositions and Methods Comprising Triazine Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-10-22 US disclosed
US-20070054998-A1 Polyacetal resin composition POLYPLASTICS CO., LTD. (JP) 2007-03-08 US disclosed
EP-1686156-A1 POLYACETAL RESIN COMPOSITION Polyplastics Co., Ltd. (JP) 2006-08-02 EP disclosed
US-3972905-A FUNGICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264433-A1 Compounds, Compositions and Methods Comprising Triazine Derivatives CFTR, PKD1, PKD2 OGG1 4671/4885KDM4E 4514/4885ALDH1A1 2483/4885
US-12024525-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GRM5, GABRA5, GABRE OGG1 2319/4885KDM4E 3498/4885ALDH1A1 1959/4885
US-12528819-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRE OGG1 2701/4885KDM4E 3607/4885ALDH1A1 2168/4885
US-20230107032-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GABRA5, GRM5, GABRA1 OGG1 2058/4885KDM4E 2690/4885ALDH1A1 1720/4885
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives CFTR, PKD1, PKD2 OGG1 3843/4885KDM4E 4565/4885ALDH1A1 2115/4885
US-12291535-B2 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment GABRA5, GRM5, GABRA1 OGG1 2058/4885KDM4E 2690/4885ALDH1A1 1720/4885
US-20230134844-A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT GRM5, GABRA5, GABRE OGG1 1834/4885KDM4E 3115/4885ALDH1A1 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.